In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA coronavirus disease 2019 (COVID-19) vaccine-associated myopericarditis was noted. Only one adolescent with life-threatening complications was reported, with no deaths at any of the participating institutions.
Keywords: mRNA COVID-19 vaccine-associated myopericarditis; outcomes; survey; variability.
Copyright © 2021 Elsevier Inc. All rights reserved.